Diabetes Clinical Trials in Austin

Showing 301-320 of 472 trials

Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects

NCT00930865

To assess the potential pharmacokinetic (PK) interactions of bumetanide and dapagliflozin following multiple doses of 1 mg bumetanide and 10 mg dapagliflozin in healthy subjects

Type 2 Diabetes Mellitus

AstraZeneca42 participantsStarted Jul 2009

Austin, Texas, United States

COMPLETEDPhase 3< 1 mile

Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control

NCT01323348

The purpose of this study is to assess whether glycemic control (assessed with HbA1c measurement) in individuals with type 1 or type 2 diabetes can be improved with a point-of-care measurement of HbA1c in the ophthalmologist's office combined with a personalized risk assessment for diabetic retinopathy and other complications of diabetes.

DiabetesDiabetic Retinopathy

Jaeb Center for Health Research1,875 participantsStarted Oct 2011

Loma Linda, California, United States • Santa Barbara, California, United States • Fort Lauderdale, Florida, United States +31 more locations

Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects

Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control

Diabetes Trials in Other Cities

Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes

Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes

Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin

Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus

A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes

Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes

24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine

Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

A Study of Dipeptidyl-peptidase IV (DPP-IV) RO4876904 in Patients With Type 2 Diabetes.

A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes

Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects

Hormone Responses During Hypoglycemia and the Accuracy of Continuous Glucose Monitors

A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin

Other Conditions in Austin